Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.7383
-0.0195 (-2.57%)
At close: Mar 28, 2025, 4:00 PM
0.7561
+0.0178 (2.41%)
After-hours: Mar 28, 2025, 7:41 PM EDT
Nektar Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Nektar Therapeutics stock have an average target of 5.50, with a low estimate of 4.00 and a high estimate of 7.00. The average target predicts an increase of 644.95% from the current stock price of 0.74.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nektar Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 3 | 3 | 3 |
| Buy | 1 | 2 | 2 | 1 | 1 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $6 | Hold → Buy | Upgrades | $6 | +712.68% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.5 | Strong Buy | Reiterates | $6.5 | +780.40% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.5 | Strong Buy | Reiterates | $6.5 | +780.40% | Feb 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.5 | Strong Buy | Reiterates | $6.5 | +780.40% | Jan 13, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +441.79% | Jan 8, 2025 |
Financial Forecast
Revenue This Year
86.95M
from 98.43M
Decreased by -11.67%
Revenue Next Year
86.32M
from 86.95M
Decreased by -0.72%
EPS This Year
-0.67
from -0.58
EPS Next Year
-0.74
from -0.67
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 136.6M | 135.1M | 216.9M | ||
| Avg | 86.9M | 86.3M | 122.0M | ||
| Low | 61.2M | 55.8M | 23.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.8% | 55.4% | 151.3% | ||
| Avg | -11.7% | -0.7% | 41.3% | ||
| Low | -37.8% | -35.8% | -73.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.36 | -0.39 | -0.23 | ||
| Avg | -0.67 | -0.74 | -0.88 | ||
| Low | -0.77 | -1.21 | -1.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.